Health Technology Assessment (HTA)
Health Technology Assessment (HTA) is a multidisciplinary process that uses explicit methods to determine a health technology’s value for healthcare decision-making. Attitudes towards HTA vary globally, with some countries using a variety of methods and analyses and others hardly any.
OHE Publishes in the Journal of Comparative Effectiveness Research: Future Expectations of Evidence of Relative Effectiveness in Europe and Comparative Effectiveness in the USA in 2020
15 April 2015
Articles co-authored by Adrian Towse, Martina Garau, Donna Messner, and Penny Mohr exploring future expectations of drug relative effectiveness in Europe and comparative effectiveness in the…
A Framework for Payer Assessment of the Value of New Technologies: A US Approach
10 March 2015
Dr Steven Pearson has convened a US policy workgroup of payers, drug and device manufacturers, patients’ groups, and clinician specialty societies to help develop a “value…
OHE Occasional Paper Critiques the Claxton et al. £13,000 per QALY Estimate
24 February 2015
OHE has published an Occasional Paper highlighting the significant shortage of data that forced Claxton et al. to rely on a large number of strong assumptions…
OHE Welcomes Dr. Aslam Anis
28 January 2015
Dr. Aslam Anis, Director of the Centre for Health Evaluation and Outcomes Sciences (CHEOS) in Canada will undertake a short sabbatical with the Office of Health…
Spotlight on OHE: Opportunity Costs of NICE Decisions in Wales and HESG 2015
20 January 2015
Jon Sussex presents on the opportunity costs of implementing NICE decisions in Wales, and OHE attend HESG in Leeds, January 2015.
Cost-per-QALY in the US and Britain: Damned if You Do and Damned if You Don’t
1 December 2015
Professor Weinstein presents a comprehensive analysis of the differences in attitudes between the US and the UK around how cost-effectiveness analysis (CEA) fits into the health…
International Decision Support Initiative (iDSI): Mapping of priority-setting in health in 17 low and middle countries across Asia, Latin America, and Africa
1 April 2015
This mapping of priority-setting considers factors such as existence of HTA institutions and commitment to UHC (Brazil, Chile, Colombia, Mexico, Uruguay, Ghana, Kenya, Malawi, South Africa,…
A Framework for Payer Assessment of the Value of New Technologies: A US Approach
1 March 2015
Dr Steven Pearson has convened a US policy workgroup of payers, drug and device manufacturers, patients’ groups, and clinician specialty societies to help develop a “value…
Spotlight on OHE: EQ-5D-5L, Next Generation Sequencing, and MCDA
19 December 2014
For information on OHE at ISPOR Europe please see earlier posts: OHE at ISPOR Europe 1 and OHE at ISPOR Europe 2. Does the choice…